Testosterone esters compared

Testosterone cypionate vs enanthate

Two long-acting testosterone esters, with each figure tied to its own label or study.

Both are oil-based injectable testosterone esters, and the US Azmiro (cypionate) and enanthate labels give the same range of 50 to 400 mg every two to four weeks.1,2 The Depo-Testosterone label gives the half-life of cypionate as approximately eight days after intramuscular injection.3

The enanthate label cites a half-life only for testosterone itself, ranging from 10 to 100 minutes.2 A 2015 study reported an apparent half-life of 172.57 hours after 200 mg of enanthate given intramuscularly to 10 men.4

FactTestosterone CypionateTestosterone Enanthate
What it isThe oil-soluble cyclopentylpropionate ester of testosterone3An ester of testosterone; esterification increases its duration of action2
How it comesOil for deep intramuscular injection: Depo-Testosterone at 100 or 200 mg/mL, Azmiro at 200 mg/mL3,1Hikma oil at 200 mg per mL in sesame oil for intramuscular use; Xyosted autoinjector, 50, 75 or 100 mg/0.5 mL, for subcutaneous use2,5
Half-life
  • Approximately eight days on the US labels3,1
  • Median 4.05 days for total testosterone in a model of healthy men7
  • Apparent 172.57 hours after 200 mg intramuscular in 10 men4
  • The Hikma label cites 10 to 100 minutes for testosterone itself2
Studied doses
  • Azmiro label: 50 to 400 mg every two to four weeks, intramuscular1
  • 200 mg intramuscular in 11 hypogonadal men: testosterone peaked on days 2 to 58
  • Hikma label: 50 to 400 mg every 2 to 4 weeks2
  • Xyosted label: starts at 75 mg subcutaneously once a week5
  • Study in men with hypogonadism: 50 or 100 mg subcutaneous each week, against men already maintained on standard 200 mg intramuscular4
StatusLabelled for testosterone replacement therapy; a Schedule III controlled substance in the US3. WADA prohibits anabolic agents (S1) at all times9Labelled for testosterone replacement therapy, delayed puberty in males and metastatic breast cancer in some postmenopausal women; a Schedule III controlled substance in the US2. WADA prohibits anabolic agents (S1) at all times9

Get the app

Contents5
  1. 1How they differ
  2. 2Logged in Milligram
  3. 3What is not known
  4. 4References
  5. 5Related pages

Last reviewed . Sources are listed below.

How they differ

Depo-Testosterone lists cottonseed oil with benzyl benzoate and benzyl alcohol as the preservative, and the Hikma enanthate label lists sesame oil with chlorobutanol as the preservative.3,2 The Azmiro label states that injectable testosterone products may have different doses, strengths or administration instructions and are not substitutable on a milligram-per-milligram basis.1

Enanthate also comes as the Xyosted autoinjector, whose label starts at 75 mg once a week.5

Logged in Milligram

  • Testosterone Cypionate: 13% of people who logged a dose in Milligram logged it in the 90 days to 15 November 2026.
  • Testosterone Enanthate: 22% of people who logged a dose in Milligram logged it in the 90 days to 15 November 2026.

Shares of people who logged a dose in Milligram in the 90 days to 15 November 2026, shown only where at least 50 people logged three or more doses of the compound.

What is not known

A 1980 study compared serum hormones after injection of enanthate and of cypionate, but its summary text is not available, so its results are not reported here.6 The 2015 enanthate study could not reliably estimate a half-life for its 50 mg subcutaneous arm because testosterone was still rising at later time points.4

The Azmiro label states that the exposure-response relationship and time course of pharmacodynamic response for testosterone have not been fully characterized.1

References

  1. Azurity Pharmaceuticals, Inc. AZMIRO (testosterone cypionate) injection, for intramuscular use, CIII (Azurity Pharmaceuticals, Inc.). US prescribing information, 2025. DailyMed label
  2. Hikma Pharmaceuticals USA Inc. Testosterone Enanthate Injection, USP (Hikma Pharmaceuticals USA Inc.). US prescribing information, 2026. DailyMed label
  3. Pharmacia & Upjohn Company LLC (Pfizer). Depo-Testosterone (testosterone cypionate) injection, USP CIII (Pharmacia & Upjohn Company LLC). US prescribing information, 2025. DailyMed label
  4. Kaminetsky J, Jaffe JS, Swerdloff RS. Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study. Phase II study, 2015. PMID 26797061
  5. Antares Pharma, Inc. XYOSTED (testosterone enanthate) injection, for subcutaneous use. US prescribing information, 2025. DailyMed label
  6. Schulte-Beerbühl M, Nieschlag E. Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate of testosterone cypionate. clinical study, 1980. PMID 7353699
  7. Bi Y, Perry PJ, Ellerby M, Murry DJ. Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects. randomized trial, population model, 2018. PMC5915615
  8. Nankin HR. Hormone kinetics after intramuscular testosterone cypionate. clinical study, 1987. PMID 3595893
  9. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. regulator list, 2026. wada-ama.org